Gerresheimer increases production capacity for pharmaceutical glass in Lohr
"We managed to install the furnace in record time thanks to the hard work and commitment of the entire team at Lohr. Without their efforts, it would never have been possible," praised Andreas Kohl, General Manager at Gerresheimer Lohr.
The brand new furnace is used in the production of transparent glass. As a result of this investment, an additional production line incorporating the very latest technology for manufacturing especially lightweight articles has been put into operation and around 16 new jobs have been created.
Gerresheimer Lohr specializes in the production of glass articles for the pharmaceutical industry. That's why all production lines have clean room technology and advanced production and inspection equipment that is certified as compliant with all the relevant standards. Customers not only expect first-rate glass, but also innovativeness and excellent results. In order to satisfy these discerning requirements and sustain its leadership, Gerresheimer Lohr uses state-of-the-art production technology and employs highly qualified production staff who receive regular further training.
The new furnace satisfies all statutory requirements of exhaust gases and air purity, and it has a completely sealed melting basin to improve energy efficiency.
Gerresheimer Lohr GmbH
Gerresheimer is an internationally leading manufacturer of high-quality specialty products made of glass and plastic for the global pharma and healthcare industry. Our comprehensive portfolio of products extends from pharmaceutical vials to complex drug delivery systems such as syringe systems, insulin pens and inhalers for safe medication dosage and application. Together with our partners, we develop solutions which set standards and have role model status in their respective market sectors.
Our Group realizes revenues of around one billion euros and has over 11.000 employees at 47 locations in Europe, North and South America and Asia. We use first-rate technologies, convincing innovations and targeted investments to systematically consolidate our strong market position.